Evoq Remedies Limited

543500

INE0JVD01011

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:58 2024-06-27 EDT			5-day change	1st Jan Change
11.68 ^INR	0.00%		+24.92%	-20.81%

06-11	Evoq Remedies Limited announced that it expects to receive INR 192.1 million in funding	CI
05-27	Evoq Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Evoq Remedies Limited Approves Resignation of Tej Hanj from the Post of Company Secretary and Compliance Officer of the Company

September 03, 2022 at 03:53 am

Evoq Remedies Limited approved resignation of Mr. Tej Hanj from the post of Company Secretary and Compliance Officer of the Company, effective 3 September, 2022.

Latest news about Evoq Remedies Limited

Evoq Remedies Limited announced that it expects to receive INR 192.1 million in funding	06-10	CI
Evoq Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-27	CI
Evoq Remedies Limited Announces Resignation of Bhumishth Patel as Managing Director	02-03	CI
Evoq Remedies Limited Approves Appointment of Gitika Mishra as Company Secretary and Compliance Officer	02-03	CI
Evoq Remedies Limited announced that it expects to receive INR 226 million in funding	01-21	CI
Evoq Remedies Bags Contract Worth INR1.4 Billion	01-10	MT
Evoq Remedies Limited Receives Export Order of INR 1,360 Million from the Marlexx Pharma Inc	01-10	CI
Evoq Remedies Limited Reports Earnings Results for the Half Year Ended September 30, 2023	11-10	CI
Evoq Remedies Limited Announces Resignation of Directors	23-09-11	CI
Evoq Remedies Limited Announces Resignation of Parth Kamdar as Company Secretary and Compliance Officer, Effective From 12 July, 2023	23-06-13	CI
Evoq Remedies Limited Approves Resignation of Tarunkumar Patel as Director	23-05-25	CI
Evoq Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-25	CI
7,210,000 Equity Shares of Evoq Remedies Limited are subject to a Lock-Up Agreement Ending on 4-APR-2023.	23-04-03	CI
Evoq Remedies Limited Announces Resignation of Bhumishth Patel as Chairman and Managing Director	23-03-31	CI
Evoq Remedies Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-07	CI
Evoq Remedies Limited Appoints Parth Kamdar as Company Secretary and Compliance Officer	22-09-03	CI
Evoq Remedies Limited Approves Resignation of Tej Hanj from the Post of Company Secretary and Compliance Officer of the Company	22-09-03	CI
Evoq Remedies Limited has completed an IPO in the amount of INR 97.2 million.	22-03-25	CI
Evoq Remedies Limited has filed an IPO in the amount of INR 97.2 million.	22-02-24	CI

EVOQ Remedies Limited is an India-based company, which is a manufacturer and supplier of pharmaceutical products. The Company is engaged in the pharmaceutical business involving marketing, trading, and distribution of a range of pharmaceutical formulation products, such as antibiotic drugs, anti-malarial drugs, anti-allergic and cold drugs, analgesic/antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, antioxidants, and injections. It offers a range of pharmaceutical formulation products, of which around 120 products are marketed by the Company under its own brand name. It also deals in the trading of active pharmaceutical ingredients (APIs). Its products include Abacavir Sulphate, Acetazolamide, Acyclovir, Adefovir Dipivoxil Allylestrenole, Alpha Beta Arteether, Alpha Lipoic Acid, Alprazolam , Amoxycillin Trihydrate, Ampicillin Trihydrate, and more.

Sector

Pharmaceuticals

Calendar

2024-11-05 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EVOQ REMEDIES LIMITED	-20.81%	1.9M
ELI LILLY AND COMPANY	+54.61%	811B
NOVO NORDISK A/S	+43.30%	640B
JOHNSON & JOHNSON	-6.33%	353B
MERCK & CO., INC.	+20.62%	333B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+17.83%	246B
ROCHE HOLDING AG	+2.41%	225B
NOVARTIS AG	+12.63%	218B
AMGEN INC.	+8.61%	168B